 |
Prospector
Profile
07.1246
|
| |
| IDM Pharma, Inc. |
NAICS |
541710 |
| 9 Parker, Suite 100
Irvine, CA 92618 |
Description |
Biotechnology |
| (949) 470-4751 |
Employees |
8 |
| http://www.idm-biotech.com/ |
Revenue |
(mil) |
11.2860 |
| |
Income |
(mil) |
-23.4550 |
| |
Assets |
(mil) |
24.3820 |
| |
Liability |
(mil) |
14.1860 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
IDM Pharma, Inc. reported a net loss of $5,741,000 on revenues of $3,118,000 for the three months ended June 30, 2007, lower than the $7,020,000 net loss on revenues of $3,036,000 reported during the same quarter last year. For the six months ended June 30, 2007, the Company reported an $11,611,000 net loss on revenues of of $5,956,000, lower than the $13,655,000 net loss on $5,300,000 reported during the first half of 2006. As a result of its recurring losses, the Company's balance sheet showed an accumulated deficit of $190,142,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company maintains a policy of filing patent applications to protect technology and products, including its Cell Drugs and other product candidates, processes for preparing product candidates, pharmaceutical compositions containing such products and, in the United States, methods of treatment of the human body. Some of its patent applications cover key technologies underlying the products in developmental pipeline and are issued or pending in jurisdictions that are key to its business. The Company classifies patents and proprietary rights into four groups: dendritic cells, macrophages, cellular technology and immuno-designed molecules. As a result of multi-country validation of its EPO patents, the patent portfolio comprised, as of January 2007, a total of 129 issued patents and 75 patent applications. In addition, the Company has been granted licenses to patents covering several products by its collaboration partners. The Company has exclusive or non-exclusive rights to 135 licensed patents covering loading and dendritic cell differentiation/maturation technologies as well as tumor antigens. It also has 2 licenses covering tumor epitopes from the National Institutes of Health and the Ludwig Institute for Cancer Research. As of February, 2007, the Company has 17 trademarks registered in the United States, Canada, France, Switzerland, Australia, Japan, Israel and Hungary, including I.D.M., The Immunogenics Company, Junovan®, Dendritophages®, Bexidem®, Uvidem®, Eladem®, Collidem® and Osidem®.
|
| |
|
Description:
The Company engages in the development of products to treat and control cancer.
|
| |
|
Officers:
Jean-Loup Romet-Lemonne, M.D. (CEO & Dir.); Hervé Duchesne De Lamotte (CFO); Robert Beck, M.D. Jean Deleage, Ph.D. Donald Drakeman, Ph.D. Sylvie Grégoire, Pharm.D. Michael G. Grey John P. McKearn, Ph.D.
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol IDMI; NasdaqGM;
25,102,709 common shares outstanding as of August 9, 2007.
|
| |
| |
| |
| return to main page |
|
|
